… Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares LEIDEN, The Netherlands, … 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands and … NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… and Drug Substance (DS) manufacturing team to lead process optimization efforts and supervise/lead tech transfer, and … are a true believer of the value of a workforce in which people from diverse backgrounds are encouraged to develop themselves, personally and professionally. We believe …
… researchers in a matrix organization. You are a natural people leader with significant experience leading and developing people in a R&D environment. In your role you will shape, support, develop and optimize the team strategy, processes and …
… are a true believer of the value of a workforce in which people from diverse backgrounds are encouraged to develop themselves, personally and professionally. We believe that happy and energized people, working well together in an environment in which they …
… initiatives that support both the growth of our people and the goals of the business. This is a hands-on, … in which people from diverse backgrounds are encouraged to develop themselves, personally and professionally. We believe that happy and energized people, working well together in an environment in which they …
… lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today … Advisory Board. As Chief ADAR Scientist, he drives the development and optimization of the Company’s Axiomer … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …